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~ Vitamin K monitoring in adult CF patients 
A. Sobanska, S. Pandya, M.J. Ledson, M.J. Walshaw. RegionalAdult CF Unit, The 
Cardiothoracic Centre, Liverpool, UK 
Introduction: As well as its role in coagulation, the importance of vitamin K 
in bone mineralisation is becoming increasingly recognised. Although there are 
currently no guidelines for vitamin K supplementation or monitoring in CF patients, 
recent evidence indicates deficiency is common in this patient group, which also 
has a high incidence of bone disorders. To investigate this further, we measured 
vitamin K levels in a subgroup of our adult CF patients. 
Method: At their routine annual screen, from a serum sample we measured vitamin 
K 1 and also prothrombin produced in vitamin K absence (PIVKA-II, a more 
sensitive measure of stored Vitamin K levels) in 16 adult CF patients (mean age 
28 years [range 18 to 44]; mean FEV1 64% predicted [range 34 to 105]; 10 male). 
Results: 10 patients (63%) had a low vitamin K 1 (<0.15 gg/1). Of these patients, 
only 1 (10%) had a BMI < 20.2 (20%) were enzyme sufficient and only 3 (30%) had 
documented liver dysfunction, with prescription of ursodeoxycholic a id. PIVKA-II 
was not detected (i.e.< 0.20AU/ml) in all 16 patients, indicating sufficient body 
stores for the production of coagulation factors. 
Conclusion: Suboptimal vitamin K status was very common in our patients, as 
indicated by low vitamin K 1 levels. Although the absence of PIVKA-II suggests 
sufficient vitamin K stores for coagulation, vitamin K requirements for optimal 
carboxylation of osteocalcin i  bone are known to be higher and stores may not be 
adequate to support his function. Further work needs to be carried out to assess 
the importance of vitamin K supplementation n adult CF patients. 
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BAn audit of low profile gastrostomy devices - is rupture of the 
internal retention balloon more common in CF? 
J. Hambleton, L. McMahon, I. Bowler. Dept of Paediatrics, Royal Gwent HosTital, 
Newport, UK 
Following a change in manufacturer's guidelines for the care of a low profile 
gastrostomy device we observed 2 ruptures of the retention balloon in a CF patient: 
the device is then at risk of falling out and the tract closing off- We audited the use 
of MicKey gastrostomy buttons in our patients. 
We identified 5 CF patients with a MicKey (4M/1F; median age 15.5y (9 
17.9)) and 10 non-CF patients (4M/6F; 10.7y (3.0 16.7)(p<0.05) with various 
diagnoses, particularly neuromuscular disorders. The medical and nursing records 
were reviewed. 
All CF patients were on long term antibiotics; 3/10 of non-CF patients. Acid 
suppressants were used in 3/5 CF patients and 5/10 non-CE All CF patients were 
receiving pancreatic enzymes. The gastric aspirate of 14/15 patients was colonised 
with candida. 
In the 5 CF patients we recorded 10 episodes of balloon rupture with 1 balloon 
intact at MicKey change. This compares to2 balloon ruptures in the non-CF patients 
with 16 balloons intact (p < 0.0001 Fisher's exact est). 
In the CF patients the median balloon life to bursting was 102 days (69~04); 1 CF 
patient's Mickey balloon was intact when changed at 110 days. In the non-CF group 
the 2 burst balloons had been in situ for 44 and 144 days (median 93.5) compared 
to a median of 82.5 days (45~80) in those not ruptured. For all patients, MicKeys 
with intact balloons needed changing at a median of 83 days compared to 102 days 
in those which had burst balloons (CI: 45 to +44; P 0.69. Mann Whitney). 
We have identified an increased rate of rupture of the retention balloon in one type 
of gastrostomy device in our CF patients. We now recommend to our CF patients 
that MicKey gastrostomy buttons are changed every 3 months or that the family 
receives in-depth training on the management of a displaced button. 
